3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
105
Skin Neoplasms
17
Neoplasm Metastasis
15
Neoplasms
10
Uveal Melanoma
9
Carcinoma, Renal Cell
9
Carcinoma, Non-Small-Cell Lung
9
Kidney Neoplasms
6
Colorectal Neoplasms
6
Carcinoma, Merkel Cell
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Lung Neoplasms
3
Carcinoma, Transitional Cell
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Prostatic Neoplasms
2
Lymphoma
2
Eye Neoplasms
2
Carcinoma, Hepatocellular
2
Urogenital Neoplasms
1
Turcot syndrome
1
Sezary Syndrome
1
Sarcoma, Synovial
1
Interventions
pembrolizumab
4
Cyclophosphamide
4
fludarabine
3
Nivolumab
3
Ipilimumab
3
Drug Therapy
3
aldesleukin
2
Biopsy
2
utomilumab
1
trastuzumab deruxtecan
1
sargramostim
1
poly ICLC
1
liposomal doxorubicin
1
fludarabine phosphate
1
erythromycin propionate-N-acetylcysteinate
1
enzalutamide
1
durvalumab
1
brodalumab
1
atezolizumab
1
advexin
1
Sirolimus
1
Radiotherapy, Conformal
1
Quality of Life
1
Psychology, Positive
1
Poly I-C
1
Patient Reported Outcome Measures
1
Observation
1
National Cancer Institute (U.S.)
1
Molecular Diagnostic Techniques
1
Microscopy, Electron
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Interleukin-2
×
Dermatologic
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled